More Cutting-Edge Cancer Research Supported by Industry
An analysis by Fox Chase suggests researchers need to be more aware of potential conflicts of interest than ever before
"The results suggest that there may be an increasing dependence on industry to support cancer research," says study author Angela R. Bradbury, MD, assistant professor in the Department of Clinical Genetics at Fox Chase. "This doesn't mean the research is flawed or biased in any way," she cautions, "but it does mean that the professional and research community has to investigate the impact of these relationships and find ways to manage any potential conflicts of interest."
Bradbury and her colleagues reviewed research submitted to the 2011 American Society of Clinical Oncology Annual Meeting, which requires all authors who want to present their findings to state if they have any relationships with industry. This includes being employed by a company, as well as owning stock, serving as a consultant or expert witness, and receiving honoraria for giving talks or participating in research projects.
They found that 48% of research accepted for presentation at the meeting in 2011 came from a group where at least one author had a relationship to industry—up from 39% of research presented in 2006. These ties to industry appeared to increase every year.
Interestingly, in a second related abstract by the same authors, Beverly Moy, MD, MPH, clinical director of the Breast Oncology Program and a medical oncologist at the Massachusetts General Hospital, reported that high profile research—selected to be presented more prominently at the meeting—was more likely to come from scientists with relationships to industry. Studies from authors with ties to industry also tended to receive higher scores from their peers.
"This finding doesn't mean that researchers with industry have some 'in' that others don't," says Bradbury. "Rather, it suggests that authors of much of the cutting-edge, clinically important research have relationships with industry."
This is not a surprise, she says, given that other sources of research funding have dried up recently. "We need money for cancer research, and it has to come from somewhere. The government has had to cut back on its support, and with the economic crisis research foundations have less money to allocate as well."
But if cancer researchers are going to continue to link up with companies that can profit from their data, the community has to be aware of the potential issues, Bradbury cautions. "If we're going to have relationships with industry, we're going to have to find ways to monitor and manage these relationships, to ensure they don't end up biasing any results."
Given that many great clinicians work with companies, patients shouldn't worry about asking their doctors if they personally have ties to industry, Bradbury reassures. "Whether or not a doctor has a relationship with a company shouldn't have any impact on patient care," she says.
Dr. Bradbury's co-authors include Beverly Moy, Jeffrey Peppercorn, Brian Egleston, Colleen B. Sands, Moktar Sheikh-Salah, Courtney Storm, and Paul R. Helft.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).